2nd Quarter - Report

ALLIANCE FOR AGING RESEARCH for ALLIANCE FOR AGING RESEARCH

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Antimicrobial resistance funding and research; heart disease; appropriations for NIH/FDA/AHRQ/CDC; Short term limited duration plans (STLDP) in Medicare; FDA guidance on Alzheimer's Disease Research; adult vaccinations in Medicare; opposition to the Balanced Budget Act; opposition to S.204/H.R.5247 Right to Try legislation

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern, Office of Representative Earl Perlmutter Extern, Office of Representative Christopher Carney
ELLEN DUNBAR JENKINS Former Senator Alan Simpson; Rep. Newt Gingrich

Contacted: SENATE; Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH)

Bills named: S. 204 (115th), H.R. 5247 (115th)

Medicare/Medicaid MMM

Short term limited duration plans in Medicare; Medicare Advantage improvements in Medicare; adult vaccines in Medicare Hospital Inpatient Prospective Payment Proposed Rule for FY2019

LobbyistCovered position, as disclosed
ELLEN DUNBAR JENKINS —

Contacted: Centers For Disease Control & Prevention (CDC); SENATE; HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS)

Budget/Appropriations BUD

Support increased funding for federal antimicrobial resistance initiatives in the President's budget. Oppose HHS proposed rule regarding short-term limited duration plans (STLDs) Oppose Right to Try bill (H.R.5247 & S.204) Support Appropriations for FY2019 for FDA, NIH, NIA, AHRQ Submitted comments to FDA re draft guidance for early Alzheimer's Disease: Developing Treatments Submitted comments to CMS re Medicare Advantage improvements Submitted comments to CMS re Medicare Program Hospital Inpatient Prospective Payment proposed rule for FY2019 in support of adult immunizations Submitted letter to Congress re H.J.Res 2 in opposition to the Balanced Budget Act

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern, Office of Representative Earl Perlmutter Extern, Office of Representative Christopher Carney
ELLEN DUNBAR JENKINS U.S. Senator Alan K. Simpson; U.S. House of Representatives Newt Gingrich

Contacted: Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; Natl Institutes of Health (NIH)

Bills named: H.J.Res. 2 (115th), H.R. 5247 (115th), S. 204 (115th)

Medical/Disease Research/Clinical Labs MED

Increased research for antimicrobial resistance; FDA guidance on early Alzheimer's Disease research

LobbyistCovered position, as disclosed
RYNE C. CARNEY —
ELLEN DUNBAR JENKINS —

Contacted: SENATE; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.